trial · primary record
Zilovertamab vedotin
B-cell Acute Lymphoblastic Leukemia
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 90 |
| Primary completion | 2029-03-31 |
| Primary endpoint | Part 1: Number of Participants from 1 to <18 years of Age Who Experience a Dose-Limiting Toxicity (DLT) |
| Registry ID | NCT06395103 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:40:30.489Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06395103
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.